| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CNS delivery via adsorptive transcytosis.
|
AAPS J
|
2008
|
1.46
|
|
2
|
Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells.
|
Biochem Pharmacol
|
2008
|
1.41
|
|
3
|
Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
|
Cancer Res
|
2004
|
1.35
|
|
4
|
ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier.
|
J Neurochem
|
2008
|
1.32
|
|
5
|
Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.
|
Mol Pharm
|
2011
|
1.25
|
|
6
|
Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein.
|
J Neurochem
|
2008
|
1.19
|
|
7
|
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.
|
Br J Pharmacol
|
2003
|
1.15
|
|
8
|
Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy.
|
Brain Res
|
2006
|
1.14
|
|
9
|
A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters.
|
Brain Res
|
2007
|
1.11
|
|
10
|
Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.
|
Mol Pharm
|
2012
|
1.09
|
|
11
|
Colchicine today.
|
Joint Bone Spine
|
2006
|
1.09
|
|
12
|
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
|
J Neurochem
|
2007
|
1.08
|
|
13
|
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).
|
Int J Neuropsychopharmacol
|
2009
|
1.04
|
|
14
|
Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
|
J Neurochem
|
2003
|
1.01
|
|
15
|
Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
|
Pharm Res
|
2007
|
1.01
|
|
16
|
Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.
|
Semin Arthritis Rheum
|
2004
|
0.98
|
|
17
|
Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
|
Mol Pharm
|
2009
|
0.96
|
|
18
|
Role of ABC transporters in the chemoresistance of human gliomas.
|
Curr Cancer Drug Targets
|
2006
|
0.93
|
|
19
|
In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
|
Pharm Res
|
2004
|
0.92
|
|
20
|
ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders.
|
Expert Opin Drug Metab Toxicol
|
2010
|
0.92
|
|
21
|
Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
|
J Nucl Med
|
2011
|
0.91
|
|
22
|
Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
|
J Pharmacol Exp Ther
|
2010
|
0.90
|
|
23
|
Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy.
|
J Pharmacol Exp Ther
|
2003
|
0.90
|
|
24
|
Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression.
|
J Cereb Blood Flow Metab
|
2011
|
0.90
|
|
25
|
Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice.
|
Crit Care Med
|
2012
|
0.90
|
|
26
|
In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain.
|
J Cereb Blood Flow Metab
|
2008
|
0.89
|
|
27
|
ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
|
J Alzheimers Dis
|
2012
|
0.89
|
|
28
|
Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier.
|
Curr Drug Metab
|
2011
|
0.89
|
|
29
|
Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2.
|
J Cereb Blood Flow Metab
|
2012
|
0.88
|
|
30
|
Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology.
|
Curr Pharm Des
|
2011
|
0.87
|
|
31
|
Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
|
Toxicol Appl Pharmacol
|
2008
|
0.86
|
|
32
|
Clonidine transport at the mouse blood-brain barrier by a new H+ antiporter that interacts with addictive drugs.
|
J Cereb Blood Flow Metab
|
2009
|
0.86
|
|
33
|
Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes.
|
Curr Drug Metab
|
2013
|
0.86
|
|
34
|
Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.
|
AAPS J
|
2013
|
0.85
|
|
35
|
Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier.
|
AAPS J
|
2012
|
0.84
|
|
36
|
Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.
|
J Neurochem
|
2012
|
0.83
|
|
37
|
Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier.
|
Drug Metab Dispos
|
2006
|
0.83
|
|
38
|
Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes.
|
J Clin Pharmacol
|
2009
|
0.82
|
|
39
|
ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
|
Pharmacol Res
|
2008
|
0.82
|
|
40
|
Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines.
|
Int J Cancer
|
2002
|
0.82
|
|
41
|
Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).
|
Toxicol Appl Pharmacol
|
2009
|
0.81
|
|
42
|
Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy.
|
J Drug Target
|
2002
|
0.81
|
|
43
|
P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes.
|
J Neurochem
|
2003
|
0.80
|
|
44
|
Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.
|
J Chemother
|
2012
|
0.80
|
|
45
|
Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels.
|
Fluids Barriers CNS
|
2011
|
0.80
|
|
46
|
Design of cocaethylene and cocaine conjugates to produce highly selective polyclonal antibodies.
|
Int J Biomed Sci
|
2006
|
0.80
|
|
47
|
Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells.
|
Neuropharmacology
|
2008
|
0.79
|
|
48
|
Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
|
Mol Pharm
|
2010
|
0.79
|
|
49
|
Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: focus on astrocytes.
|
Brain Res
|
2004
|
0.79
|
|
50
|
Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors.
|
AAPS PharmSci
|
2002
|
0.79
|
|
51
|
Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells.
|
Pharm Res
|
2003
|
0.79
|
|
52
|
Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.
|
Pharm Res
|
2012
|
0.78
|
|
53
|
Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
|
Biopharm Drug Dispos
|
2014
|
0.78
|
|
54
|
Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2.
|
J Neurochem
|
2008
|
0.78
|
|
55
|
Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
|
J Med Chem
|
2004
|
0.78
|
|
56
|
Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration.
|
Curr Pharm Des
|
2014
|
0.78
|
|
57
|
Population pharmacokinetics of 3,4-methylenedioxymethamphetamine and main metabolites in rats.
|
Toxicol Sci
|
2009
|
0.78
|
|
58
|
Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties.
|
Psychopharmacology (Berl)
|
2014
|
0.78
|
|
59
|
Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.
|
AAPS J
|
2015
|
0.77
|
|
60
|
Modulation of MDMA-induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice.
|
Addict Biol
|
2009
|
0.77
|
|
61
|
[Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier].
|
Biol Aujourdhui
|
2012
|
0.77
|
|
62
|
Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel.
|
Anticancer Drugs
|
2004
|
0.77
|
|
63
|
Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone.
|
J Pharm Sci
|
2012
|
0.77
|
|
64
|
In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier.
|
Pharm Res
|
2003
|
0.77
|
|
65
|
A physiologically based modeling strategy during preclinical CNS drug development.
|
Mol Pharm
|
2014
|
0.76
|
|
66
|
Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat.
|
Drug Metab Dispos
|
2005
|
0.76
|
|
67
|
[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.
|
Eur J Pharm Sci
|
2013
|
0.76
|
|
68
|
Covalent modifications of antitetanus F(ab')2 fragments with natural and synthetic polyamines and their effects on the antibody endocytosis in cultured HL60 cells.
|
Bioconjug Chem
|
2008
|
0.76
|
|
69
|
Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-β peptide.
|
J Alzheimers Dis
|
2013
|
0.76
|
|
70
|
Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?
|
Toxicol Appl Pharmacol
|
2006
|
0.76
|
|
71
|
Development and validation of an antigen-binding capture ELISA for native and putrescine-modified anti-tetanus F(ab')2 fragments for the assessment of the cellular uptake and plasma kinetics of the antibodies.
|
J Immunol Methods
|
2005
|
0.76
|
|
72
|
Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier.
|
J Pharm Sci
|
2009
|
0.76
|
|
73
|
Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats.
|
Biopharm Drug Dispos
|
2010
|
0.76
|
|
74
|
Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide.
|
Life Sci
|
2005
|
0.75
|
|
75
|
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.
|
AAPS J
|
2013
|
0.75
|
|
76
|
A case report of transient but clinically relevant interaction between methadone and duloxetine: a reply to McCance-Katz et al.
|
Am J Addict
|
2010
|
0.75
|
|
77
|
Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.
|
Clin Pharmacokinet
|
2014
|
0.75
|
|
78
|
Commentary: current advances and future directions for CNS delivery.
|
AAPS J
|
2008
|
0.75
|
|
79
|
Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy.
|
J Pharmacol Exp Ther
|
2005
|
0.75
|
|
80
|
Determination of 3,4-methylenedioxymethamphetamine and its five main metabolites in rat urine by solid-phase extraction and high performance liquid chromatography with on line mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2010
|
0.75
|
|
81
|
Hypoxia interferes with aryl hydrocarbon receptor pathway in hCMEC/D3 human cerebral microvascular endothelial cells.
|
J Neurochem
|
2014
|
0.75
|
|
82
|
How to obtain DNA from injection drug users?
|
Clin Chem Lab Med
|
2011
|
0.75
|
|
83
|
Peptide vectors as drug carriers.
|
Prog Drug Res
|
2003
|
0.75
|